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Abstract
Background: Bortezomib, a specific and selective inhibitor of the 26S proteasome with antitumor
activity against a wide range of malignancies, has been approved for the treatment of relapsed or
refractory multiple myeloma and other cancers. Recently, bortezomib has been identified as an
effective inhibitor of neuroblastoma cell growth and angiogenesis.
Results: In the present study, we demonstrate that some neuroblastoma cell lines are actually
resistant to bortezomib. We have sought to characterize the main pathway by which proteasome
inhibition leads to apoptosis, and to define the mechanism responsible for resistance to bortezomib
in neuroblastoma cells. Our results show that SB202190, an inhibitor of mitogen-activated protein
kinase (MAPK) p38, enhances the ability of bortezomib to induce apoptosis by preventing the
phosphorylation of the heat shock protein (HSP) 27.
Conclusion: This study opens the way to further clinical investigations and suggests a potential
benefit of using a combination of bortezomib with an inhibitor of p38 MAPK for the treatment of
neuroblastoma relapse.
Background
Neuroblastoma (NB) accounts for 8% to 10% of child-
hood cancers [1]. The two main prognostic factors are age
and stage [2,3]. Localized NB and those arising in infants
have a 90% survival rate, except in cases of MYCN ampli-
fication where survival is below 30% [3-5]. Approximately
50% of all NB occurring in children older than 1 year are
metastatic at diagnosis. NB is considered chemosensitive.
Chemotherapy is indicated in localized NB for patients
with large primary tumors in whom tumor chemoreduc-
tion allows safer surgical excision [6,7], as well as in met-
astatic NB to achieve complete remission of metastases.
The most effective drugs are alkylating agents, platinum
compounds, anthracyclines and epipodophyllotoxins [8].
High-dose chemotherapy followed by hematopoietic
stem cell transplantation and maintenance therapy with
retinoic acid improve survival by 35% in children with
metastatic NB [9,10], but the 5-year event-free survival
rate remains below 50%. Therefore, novel therapeutic
approaches are needed.
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The multicatalytic ubiquitin-proteasome pathway is
responsible for the degradation of eukaryotic cellular pro-
teins [11-14]. This adenosine 5'-triphosphate-dependent
process is vital for normal cell cycling, function and sur-
vival, making proteasome inhibition a novel therapeutic
strategy in cancer. The dipeptidyl boronic acid borte-
zomib (PS-341, Velcade® Janssen Cilag, Issy-les Mouline-
aux, France) is a specific and selective inhibitor of the 26S
proteasome [14,15]. Studies have established its antitu-
mor activity against a wide range of malignancies, includ-
ing myeloma, prostate cancer, breast cancer, colon cancer,
and lung cancer [14,16]. Recently, bortezomib became
the first proteasome inhibitor approved by the U.S. Food
and Drug Administration for the treatment of relapsed or
refractory multiple myeloma. Ongoing clinical trials of
bortezomib for prostate and lung cancers have yielded
promising results [17]. Recently, the effects of bortezomib
on human neuroblastoma cells have been studied both in
vitro and in nude mice [18,19]. Apoptosis, as well as cell
cycle and angiogenesis inhibitions have been observed,
but the molecular mechanisms by which bortezomib
induces cytotoxicity in neuroblastoma have not been ana-
lyzed. The aim of our study was to characterize the main
pathway by which proteasome inhibition leads to apopto-
sis and to define the mechanisms responsible for resist-
ance to bortezomib in several neuroblastoma cells.
Results
Effect of bortezomib on the proliferation of 
neuroblastoma cell lines
We first investigated the effect of bortezomib on cell via-
bility in vitro in 12 neuroblastoma cell lines using the Upt-
iblue assay. The cell lines were incubated with various
concentrations of bortezomib (0 to 50 nM) for 72 hours.
Results showed a dose-dependent cytotoxitic activity (fig-
ure 1). However, response to bortezomib varied signifi-
cantly with the neuroblastoma cell lines tested. IMR32,
IGRN91, CLB-Ga, CLB-Bou, CLB-Chas, CLB-Ma1, CLB-Pe,
SKNAS, CLB-Ba and CLB-Bel cell lines displayed a half
maximal inhibitory concentration (IC50) of <10 nM and
were considered sensitive to bortezomib since this con-
centration level has been defined as clinically achievable
[20] whereas CLB-Sedp and SHEP displayed higher IC50
values (> 25 nM) indicative of strong resistance to borte-
zomib.
Activation of apoptotic pathways by bortezomib
HOECHST 33258 staining revealed classic apoptotic hall-
marks such as chromatin condensation in bortezomib-
sensitive neuroblastoma cell lines, as illustrated in figure
2. The percentage of apoptotic cells observed after 72 H
treatment of neuroblastoma cell lines with 10 nM borte-
zomib was higher in sensitive than in resistant cell lines
(91%, 56.5%, 37.7% and 21% for IMR32, SKNAS, CLB-
Sedp and SHEP cell lines, respectively, vs. 23%, 20.7%,
19% and 17%, respectively, in the absence of treatment).
When the intrinsic or mitochondrial-based cell death
pathway is engaged, there is release of proapoptotic fac-
tors such as cytochrome c and SMAC/DIABLO [21] from
the mitochondria with subsequent activation of caspase 9
and other caspases such as caspases 3 and 8 [22-24].
Release of cytochrome c from the mitochondria to the
cytoplasm was detected in bortezomib-sensitive neurob-
lastoma cell lines whereas no significant variation was
observed in resistant cell lines (data not shown). Simi-
larly, a higher activation of caspase 3/7 under bortezomib
treatment was found preferentially in sensitive neuroblas-
toma cell lines (Figure 3).
Analysis of p53 mutational status
We searched whether p53 mutational status could explain
the difference in responses to bortezomib. The sequencing
of all p53 exons with their intron boundaries was per-
formed in the panel of 12 neuroblastoma cell lines. Muta-
tions were observed in CLB-Pe, CLBMa1 and SKNAS. For
SKNAS, we confirmed the truncating mutation observed
by others [25,26] with deletion of exons 10 and 11.
Misense mutations were observed in other cell lines corre-
sponding to aminoacid substitutions at codon 176
(C176F) in CLB-Pe and codon 235 (N235S) in CLB-Ma1.
Induction of proapoptotic and antiapoptotic factors under 
bortezomib treatment
Given that differences in the response to bortezomib
could not be explained by p53  mutational status, we
searched whether there was a difference among regulators
Differential sensitivity of neuroblastoma cell lines to borte- zomib Figure 1
Differential sensitivity of neuroblastoma cell lines to 
bortezomib. Cell survival in the presence of increasing con-
centrations of bortezomib was assessed by the Uptiblue 
assay at 72 h of treatment.
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of apoptosis. Among the pro-apoptotic factors studied
(p53, Noxa, PUMA, Bad, Bax, and Bak), only NOXA was
consistently induced in 6 bortezomib-treated neuroblast-
oma cell lines. An accumulation of the p53 protein was
observed in all cell lines except CLB-Pe which displayed a
mutated p53. For SKNAS, an abnormal p53 protein was
observed. These data were consistent with the results
obtained in the analysis of p53  mutational status. For
other apoptotic proteins (PUMA, Bad, Bax and Bak), no
changes in expression levels were observed (figure 4). The
antiapoptotic factors analyzed were Bcl2, Bcl-xl, Mcl-1,
XIAP and survivin. Mcl-1 was upregulated after borte-
zomib exposure in all neuroblastoma cell lines whereas
no change was identified in Bcl2, XIAP, survivin and Bcl-
xl expression after bortezomib treatment (figure 5).
Induction of heat shock proteins under bortezomib 
treatment
No obvious difference was detected between bortezomib-
sensitive and -resistant neuroblastoma cell lines during
the analysis of apoptotic and antiapoptotic factors. We
examined whether other proteins could be involved in the
resistance to bortezomib. Microarray comparisons of the
transcriptional profile of lymphoma cells resistant or sen-
sitive to bortezomib have shown that the overexpression
of heat shock proteins (HSP) is associated with borte-
zomib resistance in this cell type [27,28]. We studied the
expression of HSP27, phosphorylated HSP27, HSP70 and
HSP90 in the bortezomib-sensitive and -resistant NB cell
lines. HSP27 expression was detected in both sensitive
and resistant cells lines before and after bortezomib treat-
ment. A high pre-treatment expression and a post-treat-
ment induction of phosphorylated HSP27 (P-HSP27) was
observed in the resistant cell lines SHEP and CLB-Sedp,
whereas only moderate expression was found in sensitive
Bortezomib induces apoptosis in neuroblastoma cells Figure 2
Bortezomib induces apoptosis in neuroblastoma cells. Sensitive (IMR32 and SKNAS) and resistant (CLB-sedp) neurob-
lastoma cell lines were treated with or without 10 nM bortezomib for 72 h. Cells were stained with HOECHST 33258 (2 μl/
ml). Apoptotic cells were identified by condensation and fragmentation of nuclei using a Zeiss Axiovert inverted light micro-
scope.
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cell lines (figure 6). HSP70 was induced in all neuroblas-
toma cell lines treated with bortezomib. No change in
HSP90 expression could be observed in any neuroblast-
oma cell line after bortezomib treatment (figure 6)
Mitogen-activated protein kinase p38 inhibition enhances 
bortezomib-induced cytotoxicity against neuroblastoma 
cell lines by inhibition of HSP27 phosphorylation
As reported above, bortezomib up regulates P-HSP27
expression in resistant neuroblastoma cell lines. Previ-
ously, Hideshima et al. [29] have shown that MAPK p38
inhibition enhances the ability of bortezomib to induce
apoptosis in multiple myeloma cells. Since p38 MAPK
phosphorylates HSP27, thereby enhancing its activity, we
tested whether SB202190, a p38 MAPK inhibitor, can
increase bortezomib-induced cytotoxicity in neuroblast-
oma cell lines. The cell lines were first incubated for 30
min with various concentrations of SB202190 then
treated with different concentrations of bortezomib. The
combination of drugs increased cytotoxicity in a dose-
dependent manner (figure 7). For SHEP neuroblastoma
cells, the cytotoxic effect was initiated when SB202190
was used in association with 10 nM bortezomib and
increased when SB202190 was used in association with
25 nM bortezomib. As shown on figure 8A, this cytotoxic
effect was correlated to the inhibition of HSP27 phospho-
rylation since a decrease of P-HSP27 expression was
observed from 25 nM bortezomib when cells were prein-
cubated with SB202190. The same observation could be
made for CLB-Sedp although in this cell line the associa-
tion of SB202190 with bortezomib resulted in lower cyto-
toxicity (Figure 7). Indeed P-HSP27 protein is still slightly
expressed when the two drugs are used in association (Fig-
ure 8B). Consequently, resistance to bortezomib appears
to depend on the phosphorylation of Hsp27. Although a
low level of P-HSP27 expression was detected in the
IMR32 cell line, we observed that SB202190 also reduced
the phosphorylation of HSP27 (Figure 8C) and improved
the cytotoxic effect of bortezomib. Indeed, 5 nM borte-
zomib combined with 50 μM SB202190 were as efficient
as 10 nM bortezomib (Figure 7).
Discussion
Bortezomib is a proteasome inhibitor showing antitumor
activity in a wide range of malignancies. Despite abun-
dant evidence of the therapeutic potential of this drug, the
relevant signaling pathways leading to apoptosis in cancer
cells are not clear. In this study, we demonstrate that bort-
ezomib induces the apoptosis of neuroblastoma cells by
activation of caspases. However, the response to the drug
varies depending on the neuroblastoma cell lines tested.
Because concentration levels below 10 nM can be
observed in bortezomib-treated patients, as previously
reported by Rajkumar et al [20] and Boccadoro et al [30],
10 of the 12 neuroblastoma cell lines analyzed were
indeed identified as sensitive (IC50 <10 nM) whereas 2
were resistant (IC50 >25 nM) to bortezomib. The
response to the drug appears to be independent of the p53
mutational status. Indeed, the three neuroblastoma cell
lines for which a p53 mutation has been identified by
sequencing (CLB-Pe, CLB-Ma1 and SKNAS) and the IGR-
N91 cell line for which a p53 mutation has been identi-
fied by northern blot and western blot analyses [26,31]
remained sensitive to bortezomib. These data confirm the
results obtained by others in a variety of cancers
[18,19,32-34].
We addressed the question of which molecular mecha-
nisms were responsible for the induction of apoptosis by
bortezomib in neuroblastoma cell lines. We searched
whether members of the BCL2 family or other known reg-
ulators of apoptosis were involved. The analysis of proap-
optotic factors such as p53, NOXA, Bad, PUMA, Bax or
Bak, and of antiapoptotic factors such as Bcl2, Bcl-xl, Mcl-
1, XIAP and survivin failed to explain the differences
between NB cell lines. The accumulation of p53 and
induction of NOXA and Mcl-1 were not associated with
any major difference in response to bortezomib. Different
teams [33,34] have shown that bortezomib induces the
proapoptotic BH3-only family member NOXA in a p53
independent fashion and have identified NOXA as a key
element in the triggering of a caspase cascade culminating
in apoptosis in melanoma and myeloma cells. They have
also demonstrated the induction of Mcl-1 and survivin,
two antiapoptotic proteins known to decrease cell sensi-
tivity to bortezomib [35,36]. The overexpression of Mcl-1
reduces bortezomib-induced apoptosis by interacting
with NOXA and exerts its anti-apoptotic effect by inhibit-
Caspase activation Figure 3
Caspase activation. Analyses were performed using the 
caspase-Glo® 3/7 assay. Neuroblastoma cell lines were incu-
bated with or without bortezomib for 12 h or 24 h in four 
replicate wells. Results were expressed as the ratio of the 
mean relative light units obtained with treatment to the 
mean relative light units obtained without treatment.
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ing caspase-9 activity. Our observation of an induction of
NOXA in p53-mutated neuroblastoma cell lines con-
firmed the previous demonstration that induction of
NOXA after bortezomib exposure is p53-independent.
However, the resistant neuroblastoma cell lines tested in
our study showed reduced apoptosis in spite of high
NOXA induction, thus indicating that NOXA is not suffi-
cient to trigger apoptosis. Induction of the antiapoptotic
protein Mcl-1 cannot be the reason for this low apoptosis
reported in resistant neuroblastoma cell lines since the
protein is equally expressed in sensitive and resistant cells
after bortezomib exposure.
Abnormal HSP expression has been shown to be impli-
cated in both chemotherapeutic resistance and carcino-
genesis [37-39] and increased HSP activity appears to
result in aggressively growing, therapy-resistant tumors
[40-42]. Mitsiades et al. [43] have demonstrated that bort-
ezomib significantly upregulates antiapoptotic HSP in
multiple myeloma cells in a time-dependent manner.
Moreover, a number of constitutively activated growth
signaling pathways has been shown to play crucial roles in
regulating cell growth, metabolic responses, cell prolifera-
tion, migration and apoptosis. Constitutive activation of
protein kinases, mainly by phosphorylation, contributes
to malignant phenotypes in a number of human cancers.
Although the p38 MAPK pathway has been associated
with the induction of apoptosis in response to various cel-
lular stresses such as treatment with anticancer drugs [44],
p38MAPK activation is also central to antiapoptotic and
growth-promoting effects. For instance, Nemoto et al. [45]
have suggested that distinct members of the p38 MAPK
family have different functions in apoptosis. p38α has
been identified as a mediator and p38β as an inhibitor of
apoptosis. Other teams have described the antiapoptotic
role of p38 MAPK in a number of cell types [46,47]. p38
MAPK is known to phosphorylate HSP27, via  either
MAPK-activated protein kinase 2 (MAPKAPK2) and/or
Changes in the expression of proapoptotic factors after bortezomib treatment Figure 4
Changes in the expression of proapoptotic factors after bortezomib treatment. Neuroblastoma cell lines were 
examined either before (NT, not treated) or after 24 h of exposure to bortezomib (10 nM) and a series of Western blots (see 
methods) using specific antibodies was performed to detect relative levels of proteins. The 2 resistant neuroblastoma cell lines 
are mentioned in bold type.
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p38 MAPK-regulated/activated protein kinase (PRAK)
[48,49]. Our study shows an expression of phosphor-
ylated-HSP27 before bortezomib treatment and its induc-
tion after treatment in resistant cell lines. Combined
exposure to bortezomib and to the p38 MAPK inhibitor
SB202190 leads to enhanced apoptosis in neuroblastoma
cell lines defined as resistant to bortezomib but also
improves the cytotoxic effect observed in sensitive cell
lines. p38 MAPK inhibition prevents the phosphorylation
of the antiapoptotic protein HSP27 but does not influence
its induction, as mentioned by others [29]. Navas et al.
[50] have reported that p38 MAPK inhibition enhances
the cytotoxicity of bortezomib for multiple myeloma cells
both by inhibiting the transient expression and phospho-
rylation of HSP27 and by down regulating Bclxl and Mcl-
1 expression. Our data confirm the importance of HSP27
phosphorylation for resistance to bortezomib. However,
as no modification in Bclx and Mcl-1 expression was
observed under treatment with p38 MAPK inhibitor (Fig-
ure 8), we could not confirm that these two proteins are
involved in resistance to bortezomib. A study comparing
bortezomib-resistant and bortezomib-sensitive large B
cell lymphoma cell has identified the molecular markers
correlated with sensitivity or resistance to bortezomib
treatment. The overexpression of activating transcription
factor 3 (ATF3), ATF4, ATF5, c-Jun, JunD and caspase-3 is
associated with bortezomib-induced apoptosis whereas
the overexpression of heat shock proteins HSP27, HSP70,
HSP90 and T-cell factor 4 is associated with bortezomib
resistance [29]. Neither HSP70 or HSP90 influenced cell
resistance to bortezomib in our neuroblastoma model.
Our study shows that P-HSP27 is a key element that pro-
motes cell survival by inhibiting apoptosis, and confirms
the results obtained by other teams [51-53]. Different tar-
gets of p38 MAPK have already been identified and we
cannot exclude that other elements could be involved in
the apoptosis observed after combined SB202190-borte-
zomib treatment. Indeed, Nemoto et al. [45] have
reported that SB202190 is able to potentiate the apoptosis
induced by Fas (APO1) ligation or UV irradiation via the
stimulation of CPP32-like caspases. Furthermore, Shi et al.
[54] have shown that the inhibition of p38 MAPK results
in the suppression of anti apoptotic MAPK phosphatase-1
induction.
Changes in the expression of antiapoptotic factors after bortezomib treatment Figure 5
Changes in the expression of antiapoptotic factors after bortezomib treatment. Neuroblastoma cell lines were 
examined either before (NT) or after 24 h of exposure to bortezomib (10 nM) and a series of Western blots (see Methods) 
using specific antibodies was performed to detect relative levels of proteins. The two resistant neuroblastoma cell lines are 
mentioned in bold type.
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Conclusion
We have shown that most neuroblastoma cell lines are
sensitive to bortezomib treatment. The association of
bortezomib with a p38 MAPK inhibitor can induce cell
death in resistant cells. Various p38 MAPK inhibitors have
been developed [55]. We suggest that combinations of
bortezomib with one of the p38 MAPK inhibitors cur-
rently available could be used in relapsing neuroblastoma
patients to increase treatment response.
Methods
Reagents
Bortezomib (PS-341, Velcade®) was provided by Janssen
Cilag (Issy-les Moulineaux, France) as a lyophilized white
cake in 10-mL glass vials. Each sterile single-use vial con-
tained 3.5 mg bortezomib and 35 mg mannitol. Vials
were stored at +25°C. For in vitro experiments, the content
of each vial was dissolved in 3.5 mL of NaCl buffer (0.9%)
to a final concentration of 2.6 mM bortezomib. The
reconstituted drug was stored at -80°C then thawed and
diluted in culture medium immediately before use.
SB202190, a specific inhibitor of the mitogen-activated
protein kinases (MAPK) p38α and p38β, was purchased
from Sigma Aldrich (Saint Quentin Fallavier, France). Pri-
mary antibodies to Bcl2, BclXL, p53 (Dako, Trappes,
France), HSP27, P-HSP27, HSP70, HSP90, p38 MAPK
(Cell signaling Technology, Beverly, MA, USA), Puma
(ABcam, Paris, France), NOXA (Calbiochem, VWR Inter-
national, Fontenay-sous-bois, France), Bax, Bak, survivin
(SantaCruz Biotechnology, SantaCruz, CA, USA), Bad
(Serotec, Cergy Saint-Christophe, France), XIAP (Stress-
gen Biotechnologies, Victoria, Canada), cytochrome c and
Expression of heat shock proteins Figure 6
Expression of heat shock proteins. Neuroblastoma cell lines were examined either before (NT) or after 48 h of exposure 
to bortezomib (10 nM). Western blots using specific antibodies (see Methods) were performed to determine the expression of 
HSP27, P-HSP27, HSP70, HSP90. The two resistant neuroblastoma cell lines are mentioned in bold type.
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Inhibition of p38 MAPK increases cell death in bortezomib-resistant neuroblastoma cell lines Figure 7
Inhibition of p38 MAPK increases cell death in bortezomib-resistant neuroblastoma cell lines. The neuroblastoma 
cell lines SHEP, CLB-Sedp and IMR32 were cultured in the absence or presence of SB202190 (p38 MAPK inhibitor) for 30 min 
prior to culture with different concentrations of bortezomib for 72 h. Cell viability was assessed using the Uptiblue assay.Molecular Cancer 2008, 7:50 http://www.molecular-cancer.com/content/7/1/50
Page 9 of 12
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Down regulation of HSP27 phosphorylation by inhibition of p38 MAPK Figure 8
Down regulation of HSP27 phosphorylation by inhibition of p38 MAPK. The neuroblastoma cell lines SHEP, CLB-
Sedp and IMR32 were treated with SB202190 (50 μM) for 30 min prior to culture with different concentrations of bortezomib 
for 48 h. Expressions of HSP27, P-HSP27, HSP70, HSP90, Mcl1 and Bcl-xl were assessed by Western blot using specific anti-
bodies.Molecular Cancer 2008, 7:50 http://www.molecular-cancer.com/content/7/1/50
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Mcl-1 (BD Biosciences, Pont de Claix, France), β actin
(Sigma Aldrich) were used at dilutions recommended by
their respective manufacturers.
Cell lines and cell culture
The neuroblastoma cell lines CLB-Ga, CLB-Bou, CLB-
Chas, CLB-Ma1, CLB-Pe, CLB-Ba, CLB-Bel and CLB-Sedp
were established in our laboratory as previously described
[56]. IMR32 and SKNAS were obtained from the Ameri-
can Type Culture Collection (ATCC, Manassas, VA, USA),
and SHEP and IGR-N91 were kindly provided by M.
Schwab and J. Benard, respectively. All cell lines were
grown in RPMI 1640 (Gibco-Invitrogen, Cergy-Pontoise,
France) supplemented with 10% heat-inactivated fetal
bovine serum (Cambrex-Biowhittaker, Emerainville,
France) and 200 IU/ml penicillin, 200 μg/ml streptomy-
cin and 2 mM L-glutamine (all reagents from Gibco-Invit-
rogen) at +37°C, under 5% CO2. Cells were treated with
various concentrations of bortezomib and/or SB202190
during different time intervals.
Cell Viability Assay
Cell viability at 72 h was assessed using the Uptiblue assay
(Interchim, Montluçon, France) according to the manu-
facturer's instructions. Cells were seeded in 96-well plates
(2 × 104 cells/well). Five replicate wells were used for each
experimental condition. Different concentrations of bort-
ezomib were tested. Experiments were performed in trip-
licate for each cell line.
p53 mutation analysis
Total cellular DNA was extracted from frozen cell pellets
using phenol chloroform extraction. Exons 1 to 11 of the
p53 gene were amplified by PCR. Detailed sequences of
the primers and PCR protocols are available upon request.
The PCR products were purified with a Millipore PCR
purification kit (Millipore, Saint Quentin en Yvelines,
France) and sequenced on a 3700 sequencer (Applied Bio-
systems, Foster City, CA) using the BigDye Terminator
sequencing kit (Applied Biosystems). Sequences were ana-
lyzed using SeqScape software (Applied Biosystems).
Visualization of chromatin condensation (HOECHST 
33258 staining)
Neuroblastoma cells were treated with bortezomib (10
nM) for 72 h. Eighteen hours before visualization,
HOECHST 33258 (Sigma) was added to the culture
medium. Apoptotic cells were identified by condensation
and fragmentation of nuclei using a Zeiss Axiovert
inverted light microscope (Carl Zeiss SAS, Le Pecq,
France). Images were captured using a Power ShotG5 dig-
ital camera (Canon, Courbevoie, France).
Western Blot analysis
Cell pellets were lysed 30 min on ice in cold lysis buffer
(50 mM Tris-Hcl [ph = 7.4], 0.25 mM NaCl, 1 mM CaCl2,
50 mM NaF, 0.2% NP40) containing a protease inhibitor
cocktail (Roche, Meylan, France). Cell lysates were then
cleared by centrifugation. For the analysis of cytochrome
c release, cell pellets were resuspended in digitonin extrac-
tion buffer (phosphate-buffered saline (PBS) containing
250 mM sucrose, 70 mM KCl, 1 mM phenylmethylsulfo-
nyl fluoride, 200 μg digitonin/mL, and 1 protease inhibi-
tor cocktail tablet per 10 mL) and incubated on ice for 5
min. Samples were then centrifuged at 1,000 g for 5 min;
the pellet was removed and the supernatant was collected
and centrifuged again at 12,000 g for 15 min. The super-
natant (cytosolic fraction) was collected and the pellet
(mitochondrial fraction) was lysed in RIPA lysis buffer
(PBS containing 1% NP-40, 0.5% Na-deoxycholate, and
0.1% sodium dodecyl sulfate [SDS]) supplemented with 1
mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride,
and 1 protease inhibitor cocktail tablet per 10 mL. The
protein concentrations of all extracts were determined
using the Bio-Rad protein assay kit (Bio-Rad, Marnes-la
Coquette, France) according to the manufacturer's
instructions. Total protein (25–60 μg) was separated on
SDS polyacrylamide gel electrophoresis and transferred to
polyvinylidene fluoride membrane. After transfer comple-
tion, the membrane was blocked by incubation in 5% dry
milk in TBST (0.05% Tween 20 in TBS) and probed with
the primary antibodies, then with horseradish peroxidase-
conjugated secondary antibodies. Blots were visualized
using the ECL system (Pierce, Rockford, IL, USA).
Analysis of caspase activation
Caspase activation was determined using the caspase-Glo®
3/7 assay (Promega, Charbonnières, France) according to
the manufacturer's instructions. Cells (2 × 104 cells/well)
were seeded in black-walled 96-well plates (Greiner, Dut-
scher, Issy les Moulineaux, France) treated for 12 or 24
hours with 50 nM bortezomib and incubated 1 hour at
room temperature. Luminescence was measured with the
Cytofluor 4000 multiwell plate reader (Applied Biosys-
tems)
List of abbreviations
HSP: heat shock protein; P-HSP27: phosphorylated
HSP27; IC50: half maximal inhibitory concentration;
MAPK: mitogen-activated protein kinase; NB: neuroblast-
oma; PBS: phosphate-buffered saline; SDS: sodium
dodecyl sulfate.
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